Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Short term Debt (2021 - 2025)

Harmony Biosciences Holdings' Short term Debt history spans 5 years, with the latest figure at $20.0 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 23.08% year-over-year to $20.0 million; the TTM value through Dec 2025 reached $20.0 million, up 23.08%, while the annual FY2025 figure was $20.0 million, 23.08% up from the prior year.
  • Short term Debt for Q4 2025 was $20.0 million at Harmony Biosciences Holdings, roughly flat from $20.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $20.0 million in Q3 2025 and bottomed at $2.0 million in Q3 2021.
  • The 5-year median for Short term Debt is $15.0 million (2023), against an average of $10.9 million.
  • The largest annual shift saw Short term Debt changed 0.0% in 2022 before it surged 650.0% in 2023.
  • A 5-year view of Short term Debt shows it stood at $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022, then soared by 650.0% to $15.0 million in 2023, then increased by 8.33% to $16.2 million in 2024, then grew by 23.08% to $20.0 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Short term Debt are $20.0 million (Q4 2025), $20.0 million (Q3 2025), and $18.8 million (Q2 2025).